Pamela Bassett

Special to RealMoney.com

Pamela Bassett is a biopharmaceutical analyst and president of BioTrend. Bassett has published extensively on emerging technologies and strategy in biopharmaceuticals. Bassett was formerly director of business development for Enzon; prior to that, she provided advisory services to telecom, software and biotech companies on new product and emerging market development. She was also the founder and president of Stat Systems, a company that developed clinical and administrative software systems used in hospitals nationwide. Bassett received her master's degree in business administration from Wharton Graduate School, University of Pennsylvania; completed a residency in Anesthesiology at the Medical College of Pennsylvania and Hospital; received her doctorate degree of dental medicine from Tufts University School of Dental Medicine; and earned a bachelor's degree in biology from Oakland University.
Pamela Bassett
By This Author:
« Back
Page 1 of 2
Article

Antigenics' Pipeline Looks Like a No-Go (RealMoney.com $)

By Pamela Bassett

Oncophage is a long shot for FDA approval, and it faces steep challenges even if it gets the regulatory thumbs-up.

11:35AM 06/17/05

Article

Antigenics' Pipeline Looks Like a No-Go

By Pamela Bassett

Oncophage is a long shot for FDA approval, and it faces steep challenges even if it gets the regulatory thumbs-up.

11:33AM 06/17/05

Article

ImmunoGen Poised to Tap Growth (RealMoney.com $)

By Pamela Bassett

The company's cancer technology has it at a crossroads of opportunity.

10:14AM 05/31/05

Article

Medarex Faces Post-ASCO Questions (RealMoney.com $)

By Pamela Bassett

The company's long-term promise remains intact, but the short-term troubles in its ASCO data raise caution flags.

03:45PM 05/17/05

« Back
Page 1 of 2

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
Dow Jones S&P 500 NASDAQ 10-Year Note
12,459.60 1,318.05 2,830.82 17.72
Oil *
106.36
DOWN
36.55
DOWN
0.81
DOWN
19.30
UP
0.51
10 Yr
1.77%
SPDR Gold
152.25
-0.29%
-0.06%
-0.68%
+2.96%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet